HC Wainwright Reaffirms Buy Rating for OKYO Pharma (NASDAQ:OKYO)

HC Wainwright reissued their buy rating on shares of OKYO Pharma (NASDAQ:OKYO) in a research note released on Monday,Benzinga reports. The brokerage currently has a $7.00 price target on the stock.

OKYO Pharma Stock Performance

Shares of NASDAQ OKYO opened at $1.09 on Monday. OKYO Pharma has a 52-week low of $0.81 and a 52-week high of $1.90. The stock’s fifty day simple moving average is $1.09 and its 200 day simple moving average is $1.07.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.